Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

The answer turned out to be a cutting-edge treatment that few Americans know about, according to Roswell Park Comprehensive ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

A benefit and auction will be held for Ayla Marecek, 16, on April 27 at the VFW Hall, 2497 N. US 27 in St. Johns to help ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

It’s probably an understatement to say that Luca Bertucci had some strong motivation to raise money for cancer research funding. After in-patient chemotherapy during his sophomore year of school ...

Kamdar was recruited from Stanford in 2015 to start the lymphoma programme at CU Anschutz. Her goal was to focus on aggressive lymphomas by creating more effective, less toxic treatments that ...

For slow-growing lymphomas, long-term survival is common, although they cannot be cured. More aggressive tumors are more dangerous, but a permanent cure is possible. The lymphoma type, its effects ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...